title: The calcium channel blocker nisoldipine delays progression of chronic renal failure in humans (preliminary communication).
abstract: Chronic renal failure (CRF) patients with a stable course were asked to participate in a follow-up program in which they were randomized into two groups: 1) the placebo group taking their standard antihypertensive therapy without any calcium ion blocker: and 2) the nisoldipine group, those patients taking the calcium channel blocker nisoldipine as the only antihypertensive drug. The two groups had similar blood pressures on entering the study (151 +/- 21.3/90.7 +/- 7.4 mmHg in the nisoldipine and 146.7 +/- 18/94 +/- 9.4 mmHg in the placebo group). Their protein intake was also similar (daily average throughout the follow-up period: 0.83 +/- 0.18 g protein per kg body weight in the nisoldipine and 0.9 +/- 0.12 g in the placebo group). The patients were checked monthly. The follow-up averaged 11.1 +/- 4.8 months in the nisoldipine group and 13.7 +/- 4.2 months in the placebo group. The rate of progression of CRF, as expressed by the slope of the regression line of 1/serum creatinine versus time, decreased in the nisoldipine group from the initial (-8.03 +/- 4.91) x 10(-3) to (-5.57 +/- 5) x 10(-3) (two-tailed P-test = 0.016) after intervention. The slopes tended to become steeper in the placebo group, with an initial slope of (-4.1 +/- 3.2) x 10(-3) changing to (-7.9 +/- 5) x 10(-3) after intervention. This difference did not reach statistical significance (two-tailed P = 0.072). The rate of progression of CRF decreased in 12 of 14 patients in the nisoldipine-treated group versus 3 of 11 patients in the placebo group.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Nephrology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
authors.forename: H E
authors.initials: HE
authors.lastname: Eliahou
authors.forename: D
authors.initials: D
authors.lastname: Cohen
authors.forename: A
authors.initials: A
authors.lastname: Ben-David
authors.forename: D
authors.initials: D
authors.lastname: Herzog
authors.forename: I
authors.initials: I
authors.lastname: Serban
authors.forename: S
authors.initials: S
authors.lastname: Gavendo
authors.forename: S
authors.initials: S
authors.lastname: Kapuler
authors.forename: N
authors.initials: N
authors.lastname: Kogan
authors.forename: B
authors.initials: B
authors.lastname: Hellberg
mesh_terms: D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004044:Dietary Proteins / Q000378:metabolism; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D008875:Middle Aged; D015737:Nisoldipine / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D002121:Calcium Channel Blockers; D004044:Dietary Proteins; D015737:Nisoldipine